Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use
Break the Cycle: Adapting Break the Cycle to Reduce Initiation Into Injecting Drug Use in Tallinn, Estonia and New York City, USA
Break the Cycle is a two-session, one-on-one, in-person intervention study designed to reduce the role persons who inject drugs (PWID) play initiating non-PWID into injection drug use. Study implementation is at two sites: New York City and Tallinn, Estonia. At baseline, quantitative data are collected via a structured computer-assisted personal interview, after which the intervention is conducted. At the 6-month follow-up, a modified version of the interview is repeated.
In Tallinn, and in it's first iteration in NYC, Break the Cycle used a pre- versus post- design to compare the proportion of participants who helped with first injections, and who promoted injecting among non-PWID, in the 6 months prior to baseline with the proportions at the 6-month follow-up. Based on previous research on the intervention and on the underlying theory of motivational interviewing, increases in helping and promoting behaviors between baseline and follow-up would indicate that the intervention was not effective regardless of their effect size. Accordingly, the hypotheses that the intervention will produce reductions in assisting with first injections and engaging in injection promoting behaviors will be evaluated using one-tailed statistical tests. Break the Cycle intervention follows a motivational interviewing approach to enhance current injectors' motivation and skills to avoid helping with and promoting first injections among non-PWID. The intervention's core is a discussion between an interventionist and each participant on the following eight topics: the participant's first time injecting drugs; the participant's exposures to situations where helping with others' first injections is an option, and the extent to which they have helped; PWIDs' behaviors that might encourage non-PWID to inject for the first time; the range of risks associated with injection drug use; role-playing scenarios in which the participant develops behaviors and scripts for avoiding or refusing requests to initiate others into injection drug use; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using Narcan to reverse overdoses.
In the second iteration of Break the Cycle in New York City, a second arm to the trial was added: an attentional control intervention, Bacterial Infection Prevention. The content of Bacterial Infection Prevention is representative of the infection prevention information injection drug users ought to receive, and sometimes do, when they engage with service providers, such as syringe exchange programs. Bacterial Infection Prevention does not use Motivational Interviewing principles, but is more informational/educational in nature. This intervention focuses on bacterial infection risks that accompany injection drug use, with a special focus on risk reduction, identification, and treatment of abscesses and endocarditis. Participants eligible for Break the Cycle are randomized to either receive the Break the Cycle intervention or the Bacterial Infection Prevention intervention. Enrollment in this iteration ended in March 2020, with the advent of the Covid pandemic in the United States.
The third iteration of the Break the Cycle intervention in New York City will transform the second iteration into a phone-based study in which both Break the Cycle and Bacterial Infection Prevention are delivered to participants over the telephone. Both interventions have been slightly abbreviated to adjust to phone delivery. This iteration will commence in early spring, 2021.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: David M. Barnes, PhD
- Phone Number: 212-992-3729
- Email: barned05@nyu.edu
Study Locations
-
-
-
Tallinn, Estonia
- University of Tartu
-
-
-
-
New York
-
New York, New York, United States, 10012
- New York University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- have injected drugs non-medically in the last 2 months
- able to provide informed consent
- age 18 or older
- able to participate in the interview and intervention in English (in New York City), Russian or Estonian (in Tallinn, Estonia)
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Break the Cycle Intervention
Break the Cycle intervention uses motivational interviewing to enhance current injectors' motivation and skills to avoid helping with and promoting first injections among non-PWID.
|
The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting.
The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
|
|
Active Comparator: Bacterial Infection Prevention
Bacterial Infection Prevention is an attention control intervention.
The content of Bacterial Infection Prevention is representative of the infection prevention information injection drug users ought to receive, and sometimes do, when they engage with service providers, such as syringe exchange programs.
Bacterial Infection Prevention does not use Motivational Interviewing principles, but is more informational/educational in nature.
This intervention focuses on bacterial infection risks that accompany injection drug use, with a special focus on risk reduction, identification, and treatment of abscesses and endocarditis.
|
Bacterial Infection Prevention is an attention control intervention.
The content of Bacterial Infection Prevention is representative of the infection prevention information injection drug users ought to receive, and sometimes do, when they engage with service providers, such as syringe exchange programs.
Bacterial Infection Prevention does not use Motivational Interviewing principles, but is more informational/educational in nature.
This intervention focuses on bacterial infection risks that accompany injection drug use, with a special focus on risk reduction, identification, and treatment of abscesses and endocarditis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants helping with first injections
Time Frame: 6 months
|
Number of participants who helped persons who do not inject drugs with a first injection
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants who say positive things
Time Frame: 6 months
|
Number of participants who saying positive things about injecting to persons who do not inject drugs
|
6 months
|
|
Number of participants injecting in front of other people
Time Frame: 6 months
|
Number of participants injecting in front of people who do not inject drugs
|
6 months
|
|
Number of participants offering to give first injection
Time Frame: 6 months
|
Number of participants offering to give a first injection to persons who do not inject drugs
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Anneli Uuskula, PhD, University of Tartu
- Principal Investigator: Don Des Jarlais, PhD, New York University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GCO 15-1445
- 5DP1DA039542-05 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Abuse, Intravenous
-
NCT03940729CompletedIntravenous Drug Abuse, S Aureus Colonization
-
NCT03869671WithdrawnIntravenous Drug Abuse
-
NCT05794984CompletedTelemedicine | Social Media | Drug Abuse, Intravenous | Internet
-
NCT02487745CompletedSubstance Abuse, Intravenous
-
NCT05360849Active, not recruitingHIV | Primary Prevention | Women's Health | Implementation Science | Intravenous Substance Abuse | Organization and Administration
-
NCT05679284RecruitingSoft Tissue Injuries | Substance Dependence | Foreign Bodies | Drug Abuse, Intravenous | Needle Injury
-
NCT01031745CompletedSubstance Abuse, Intravenous | HIV
-
NCT01128920CompletedIntravenous Drug Abuse | HIV Infections
-
NCT00471042CompletedSubstance Abuse, Intravenous | Opioid-Related Disorders | Heroin Dependence
Clinical Trials on Break the Cycle Intervention
-
NCT02602730CompletedCigarette Smoking | Smoking, Tobacco
-
NCT02774954CompletedSubstance Abuse, Intravenous | HIV | Heroin Dependence | Opioid Dependence | Cocaine Dependence | Amphetamine Dependence
-
NCT05810519Completed
-
NCT06268678CompletedMuscle Protein Synthesis | Menstrual Cycle Phase
-
NCT04093037Completed
-
NCT04027049CompletedAcute Ischemic Stroke | Intracerebral Hemorrhage
-
NCT05768815RecruitingSubstance Use | Mother-Child Relations
-
NCT03752892Active, not recruitingLung; Disease, Interstitial, With Fibrosis